Selected News

SEATTLE, February 28, 2024 —Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer. Mr. Russell brings a wealth of experience working with both emerging growth companies […]

Collaboration to leverage Umoja’s VivoVecTM gene delivery platform and AbbVie’s expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE, WA. Jan. 4, 2024 — AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to

SAN JOSE, CALIFORNIA,  SHANGHAI, NANJING, CHINA, AND SEATTLE, WASHINGTON, January 03, 2024 –IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced a new set of collaborations with Umoja Biopharma, Inc. (“Umoja”), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend